Bioxytran Inc (BIXT)

[ProfitScout]

Excellent enhancement of the BIXT scientific team announced today with the addition of Juan Carlos Lopez-Talavera, MD, PhD who comes from a major biomedical industry background. There is no question that he will make great contributions for Bioxytran.

Note Dr. Lopez-Talavera's comments:

“In my professional career I have always gravitated toward working with novel mechanisms. “ said Dr. Lopez-Talavera. ”The opportunity at Bioxytran is so vast, because tissue oxygenation represents a true unmet medical need and represents a tremendous untapped opportunity to target both the Ischemic Stroke and, has future potential for Acute Respiratory Distress Syndrome (“ARDS”). BXT-25 has the unique ability to deliver oxygen through a small molecule which can be effective in extending the “golden hour” in stroke victims and potentially for tissue regeneration in ARDS victims. I am honored to be part of this team and look forward to advancing the science and creating partnerships or joint ventures that will grow this field of research.”